IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking ago... IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. 詳細を表示
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.16 | 2.44648318043 | 6.54 | 6.77 | 5.79 | 303905 | 6.16747697 | CS |
4 | -3.3 | -33 | 10 | 10.8 | 5.79 | 238716 | 7.20117558 | CS |
12 | -7.19 | -51.7638588913 | 13.89 | 20.35 | 5.79 | 234523 | 11.05249925 | CS |
26 | 0.23 | 3.55486862442 | 6.47 | 22.5 | 5.79 | 290881 | 12.091583 | CS |
52 | -1.87 | -21.8203033839 | 8.57 | 22.5 | 5.79 | 296926 | 11.24832573 | CS |
156 | -23.03 | -77.4638412378 | 29.73 | 35.98 | 3.81 | 353386 | 16.51905379 | CS |
260 | -28.32 | -80.8680753855 | 35.02 | 127.11 | 3.81 | 282560 | 29.18342635 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約